HIPRA, an EU-based biopharma company, was developing a recombinant protein vaccine against SARS-COV-2 and was looking for an experienced partner to work with in order to improve the adoption of its vaccine in global markets.
April 30, 2024
Pharmaceutical Partner Introducing New Sterile Vaccine Product
Might interest you
View All
Global Health
Delivering Every Dose Better: Frontline Interviews
These frontline interviews and user testing sessions are invaluable sources of feedback that allow our engineers to design and manufacture modifications to better serve these constituencies’ needs
Global Health
ApiJect Systems Receives Grant to Develop Low-Cost Blow-Fill-Seal Prefilled Injection Device for Low- and Middle-Income Countries
Grant will fund the design and development of an affordable, multi-month contraceptive delivery device to enhance access in Low- and Middle-Income Countries (LMICs). Blow-Fill-Seal will be explored for the container closure and subcutaneous injection delivery system, advancing a concept initially developed by...
BFS Technology
The Advantages of BFS: Global Delivery Systems
A global delivery system for injectable drugs around the world has been hampered by many things. Production of glass vials, incredibly complicated, and fragile items.